Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.
| Health Care Equipment & Supplies Industry | Healthcare Sector | James Patrick Mackin CEO | XDUS Exchange | US2289031005 ISIN |
| US Country | 1,800 Employees | 12 Mar 2014 Last Dividend | 28 Dec 2000 Last Split | - IPO Date |
Artivion, Inc., initially known as CryoLife, Inc., before its name change in January 2022, is a prominent entity in the medical devices and implantable human tissues sector, with operations extending globally. Founded in 1984 and based in Kennesaw, Georgia, the company is adept at manufacturing, processing, and distributing a wide array of medical devices. These products are designed for use in various medical procedures, including cardiac, vascular, neurologic, and pulmonary operations. Artivion, Inc. caters to a diverse clientele, including physicians, hospitals, and other healthcare facilities, with its offerings significantly influencing the practices of cardiac, vascular, thoracic, and general surgeons across the world.